Frontiers | Emerging Topical and Systemic JAK Inhibitors in Dermatology | Immunology
Translational and clinical advances in JAK‐STAT biology: The present and future of jakinibs - Gadina - 2018 - Journal of Leukocyte Biology - Wiley Online Library
JAKs and STATs in Immunity, Immunodeficiency, and Cancer | NEJM
APExBIO - JAK/STAT Signaling - Signaling Pathways
Signalling through the JAK–STAT pathway in the developing brain: Trends in Neurosciences
The role of JAK/STAT signaling pathway and its inhibitors in diseases - ScienceDirect
JAK-STAT signaling pathway - Wikipedia
JAK inhibitors in dermatology: The promise of a new drug class - Journal of the American Academy of Dermatology
A MicroRNA-1–Mediated Inhibition of the NF-κB Pathway by the JAK-STAT Pathway in the Invertebrate Litopenaeus vannamei | The Journal of Immunology
SOCS induction by and inhibition of the JAK/STAT pathway. (1)... | Download Scientific Diagram
Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19: Trends in Pharmacological Sciences
JAK–STAT pathway targeting for the treatment of inflammatory bowel disease | Nature Reviews Gastroenterology & Hepatology
PathwayReady JAK/STAT Signaling Inhibitor Panel biochemical
The role of JAK/STAT signaling pathway and its inhibitors in diseases - ScienceDirect
Ruxolitinib (INCB018424) | ≥99%(HPLC) | Selleck | JAK inhibitor
Frontiers | “Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway | Oncology
Rheumatoid arthritis | JAK inhibitors: The next generation of drugs for treating rheumatoid arthritis? | rheumatology.medicinematters.com
Cells | Free Full-Text | Targeting the JAK/STAT Signaling Pathway Using Phytocompounds for Cancer Prevention and Therapy | HTML
The Potential of JAK/STAT Pathway Inhibition as a New Treatment Strategy to Control Cytokine Release Syndrome in COVID-19 | Biological and Medicinal Chemistry | ChemRxiv | Cambridge Open Engage
JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis
Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma - Journal of Hepatology
JAK/STAT signaling - My Cancer Genome
Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application | Biomarker Research | Full Text
JCI - JAK inhibitors in autoinflammation
Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases | SpringerLink
